Professor Qing Yi
Qing Yi, MD, PhD, is Chair and Staff, Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic.
Dr Yi is one of the leading investigators in the field of immune regulation and immunotherapy in multiple myeloma. He has been working on characterizing myeloma-specific T cells and their subsets, and examining their functions in relationship to myeloma tumor cells in both in vitro and in vivo experiments, and on identifying novel myeloma-associated antigens for immunotherapy. In addition, Dr Yi has been conducting clinical trials to evaluate the efficacy of immunizing patients with idiotype or dendritic cell-based vaccines. His research will continue focusing on the development of effective immunotherapy strategies to cure myeloma patients in combination with high-dose chemotherapy.
Recently, Dr Yi and his group discovered that anti-β2-microglublin antibodies could kill myeloma cells. His research team is thus examining whether these antibodies have therapeutic potentials to treat patients with myeloma. Furthermore, his recent studies demonstrate that C-reactive protein (CRP) protects myeloma cells from chemotherapy drug-induced apoptosis, and further work is under way to explore whether CRP can be targeted for myeloma therapy. Dr Yi’s research has been supported by US federal and foundation grants since 1998, and he has authored over 120 papers in the fields of myeloma research, immunotherapy of cancer, and tumor biology.